Posard Matthew L. is a director of Nautilus Biotechnology Inc.
Person profile
Roles
Address
La Jolla, California
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
HALOZYME THERAPEUTICS, INC.
29 Apr 24
4
Nautilus Biotechnology, Inc.
16 Jun 23
4
Talis Biomedical Corp
12 Jun 23
4
DermTech, Inc.
5 Jun 23
4
HALOZYME THERAPEUTICS, INC.
9 May 23
4
HALOZYME THERAPEUTICS, INC.
6 Dec 22
4
Nautilus Biotechnology, Inc.
16 Jun 22
4
Talis Biomedical Corp
13 Jun 22
4
DermTech, Inc.
31 May 22
4
HALOZYME THERAPEUTICS, INC.
6 May 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Apr 24 | HALO Halozyme Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 6,501 | 0.00 | 119,755 |
25 Apr 24 | HALO Halozyme Therapeutics | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 38.46 | 8,804 | 338.60 k | 8,804 |
15 Jun 23 | NAUT Nautilus Biotechnology | Stock Option Common Stock | Grant | Acquire A | No | No | 3.97 | 45,000 | 178.65 k | 45,000 |
9 Jun 23 | TLIS Talis Biomedical | Stock option Common Stock | Grant | Acquire A | No | No | 0.5 | 95,000 | 47.50 k | 95,000 |
1 Jun 23 | DMTK DermTech | Common Stock | Grant | Acquire A | No | No | 0 | 35,714 | 0.00 | 158,215 |
5 May 23 | HALO Halozyme Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 8,065 | 0.00 | 113,254 |
5 May 23 | HALO Halozyme Therapeutics | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 31 | 11,371 | 352.50 k | 11,371 |